Navigation Links
European Union's CHMP Issues Positive Opinion on Sugammadex
Date:6/2/2008

Anesthesiologists to have new tool that works within minutes, upon European

approval

KENILWORTH, N.J., June 2 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has recommended approval of sugammadex for routine reversal of the muscle relaxants rocuronium or vecuronium and for immediate reversal of rocuronium in adults, and for routine reversal following rocuronium in children and adolescents (2-17 years of age). Rocuronium and vecuronium are marketed in Europe under the trade names ESMERON(R) and NORCURON(R), respectively.

The CHMP recommendation serves as the basis for a European Commission approval of this novel medicine. Upon European approval, sugammadex will be the first and only selective relaxant binding agent (SRBA) and will enable anesthesiologists to rapidly and predictably reverse both moderate and deep muscle relaxation induced by rocuronium and vecuronium. Sugammadex creates the opportunity for anesthesiologists to maintain optimal muscle relaxation to the end of a surgical procedure and to reverse the block in minutes.

"This is an important first step in realizing the promise of our Organon BioSciences acquisition," said Fred Hassan, chairman and CEO of Schering- Plough. "This was a relatively unknown asset before our acquisition announcement last March, and we are pleased we saw this opportunity."

"This product has the potential to modernize the use of anesthesia around the world," added Thomas P. Koestler, Ph.D., executive vice president and president, Schering-Plough Research Institute.

Muscle relaxants play several critical
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PLC Systems Announces Approval of First European Study to Evaluate RenalGuard(TM)
2. PRoFESS(R) Results Announced at XVII European Stroke Conference
3. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
4. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
5. European Medicines Agency Adopts Positive Opinion for Ranolazine for Treatment of Chronic Angina
6. More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL
7. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
8. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
9. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
10. Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market
11. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 /PRNewswire-iReach/ -- VAPETEK™, ... a vegetable-glycol solution for use in portable vaporizers, ... the active ingredients in cannabis, cannabidiol offers consumers ... vaporizer devices, and other vaporizer technology. ... Cannabis naturally contains 483 different compounds which are ...
(Date:7/11/2014)... , July 11, 2014 Patient ... marketing and, consequently, organizations are turning to an ... As part of this evolving approach ... to educate, communicate and engage patients throughout their ... to patient empowerment. By mapping the patient journey ...
(Date:7/11/2014)... 2014 The consumer marketing playbook and ... sectors to better identify winning tools and techniques. ... with and understand consumers, as new technologies are ... purchasing decisions. According to recent ... area where organizations can observe a deep pool ...
Breaking Medicine Technology:VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2New Technologies Transforming Consumer Marketing Research Playbook 2
... TUCSON, Ariz., April 26, 2012  SynCardia Systems, Inc. ( ... FDA, Health Canada and CE (Europe) approved Total Artificial ... two-time Olympian, Gaetano "Gates" Orlando, has become the first ... SynCardia temporary Total Artificial Heart . The 49-year-old, who ...
... (Nasdaq: MYL ) today announced its financial results for ... Results , Adjusted diluted EPS of $0.52 for the ... same prior year period, an increase of 18%; , ... March 31, 2012 compared to $1.45 billion for the same prior ...
Cached Medicine Technology:Retired Pro Hockey Player 1st to Receive Total Artificial Heart in Upstate New York 2Retired Pro Hockey Player 1st to Receive Total Artificial Heart in Upstate New York 3Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 2Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 3Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 4Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 5Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 6Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 7Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 8Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 9Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 10Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 11Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 12Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 13
(Date:7/13/2014)... Seattle, WA (PRWEB) July 13, 2014 According ... Vkool.com, this is a step by step guide on what ... impairment easily and quickly. Vkool writes in its review ... what foods to eat to revitalize their kidney health. Vkool ... book can help people reverse their damaged kidney functions naturally. ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Wright & ... trial has been scheduled in July of 2015, in ... Lipitor lawsuits are in the discovery process in ... M. Gergel is presiding over the multidistrict litigation (MDL). ... on behalf of individuals who allege that they took ...
(Date:7/13/2014)... 13, 2014 A Xarelto lawsuit ... LLC to provide consumers with the most current information ... of the blood-thinning medication, as well as the ... courts around the country. The law firm is now ... suffered from life-threatening internal bleeding and related complications while ...
(Date:7/13/2014)... July 13, 2014 Celebrity fitness trainer ... formed a promotional partnership with Aqua Health Labs for ... Omega-3 EPA supplement . The collaboration was recently announced ... fitness trainer , actor, model, and a two ... for A-List celebrities, he has prepared stars including Demi ...
(Date:7/13/2014)... ECS is being founded by ... of a special needs child, I have become keenly ... for contemporary special education resources and evidence-based instruction. Emerald ... and families in the Seattle metro area that are ... education. We welcome the opportunity to serve our community ...
Breaking Medicine News(10 mins):Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 2Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 2Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 4Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2Health News:New Private School, Emerald City School, Founded in Downtown Seattle Now Accepting 1st to 6th Grade Students Who Learn Differently 2
... that instruction alone is no guarantee , , MONDAY, March ... lessons doesn,t increase their risk of drowning, says a ... that swimming lessons could actually increase drowning risk by ... in and around water. , U.S. government researchers ...
... Heartland report uncovers staggering shortfall in meals needed to ... to start filling the gapSAINT PAUL, Minn., March 2 ... the Upper Midwest,s leading voice on hunger relief, today ... every year--the equivalent of those in need going to ...
... Seattle, WA; Ogden, UT March 2, 2009) ... States show that educational materials aimed at preventing shaken ... crying, which is the number one trigger for people ... mothers to warn babysitters about shaken baby syndrome and ...
... abortion corruption; OR urges supporters to immediately contact ... March 2 Operation Rescue has vowed to ... as Secretary of Health and Human Services with ... a unified voice in the pro-life/pro-family community against ...
... says, , , MONDAY, March 2 (HealthDay News) -- Elderly women who ... normal to break a hip within a year after the arm ... efforts to prevent both types of fractures. , "There have ... fractures and hip fractures, but we wanted to determine when that ...
... drugs designed to starve tumors of their blood supply ... more invasive cancer growthsometimes with a higher incidence of ... research clarifies similar findings in other animal studies and ... number of clinical trials with cancer patients. , "People ...
Cached Medicine News:Health News:Swimming Lessons Don't Increase Drowning Risk, Study Says 2Health News:Missing: 125 Million Meals for Low-Income Minnesotans 2Health News:Missing: 125 Million Meals for Low-Income Minnesotans 3Health News:Missing: 125 Million Meals for Low-Income Minnesotans 4Health News:Educational materials increase knowledge and behaviors important for preventing shaken baby syndrome 2Health News:Educational materials increase knowledge and behaviors important for preventing shaken baby syndrome 3Health News:Operation Rescue Launches Opposition to Gov. Sebelius' Confirmation as HHS Secretary 2Health News:Operation Rescue Launches Opposition to Gov. Sebelius' Confirmation as HHS Secretary 3Health News:In Elderly Women, Hip Fractures Often Follow Arm Breaks 2Health News:Study sheds light on angiogenesis inhibitors, points to limitations, solutions 2Health News:Study sheds light on angiogenesis inhibitors, points to limitations, solutions 3Health News:Study sheds light on angiogenesis inhibitors, points to limitations, solutions 4
Product includes all 15 Lexi-Comps databases. Includes Lexi-drugs, the official reference of the American Pharmacists Association and the National Professional Society of Pharmacists....
... Knife with BD Xstar Blade includes a ... the blade in prodedure and handling. ... a grind-less process for manufacturing surgical blades. ... and consistency. The arch style, single-bevel ...
Electric high speed system....
The Durafuge 100 spins swing-out rotors at 4000 rpm and fixed-angle rotors at up to 6300 rpm....
Medicine Products: